Antibiotic resistant fecal isolates of Enterococci among unselected patients outside the clinical sector: An epidemiological study from Southern Germany

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 4, 2006, Pages 275-277

  Lietzau, S ^a   Hoewner, M ^a   von Baum, H ^b   Marre, R ^b   Brenner, H ^a  

^a GERMAN CENTRE FOR RESEARCH ON AGEING   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Antibiotics; Bacterial infections; Community; Drug resistance; Enterococci

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; IMIPENEM; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG USE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FECES CULTURE; GENERAL PRACTITIONER; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTPATIENT; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; AMPICILLIN; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DOXYCYCLINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FECES; FEMALE; GERMANY; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE;

EID: 33646054103     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1167     Document Type: Article

References (10)

1. Murray BE. Vancomycin-resistant enterococci. Am J Med 1997; 102: 284-293.
2. Huycke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future. Emerg Infect Dis 1998; 4: 239-249.
3. Kresken M, Hafner D. Studiengruppe. Development of antibiotic resistance in clinically relevant microorganisms in central Europe. Results of a longitudinal study of the Study Group' Bacterial Resistance' Paul-Ehrlich Society for Chemotherapy in 1998. Chemotherapie J 2000; 9: 51-86 [German].
4. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA. Studiengruppe. Development of antibiotic resistance in clinically relevant microorganisms in central Europe. Results of a longitudinal study of the Study Group' Bacterial Resistance' Paul-Ehrlich Society for Chemotherapy in 2001 Antiinfectives Intelligence, Bonn, 2003 [German] http://www.antiinfectives-intelligence.de/peg/ag_resistenz/ peg_resistenzstudie_2001.pdf Cited 29 April 2004.
5. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710-721.
6. Marre R, Scheringer I, Erb A, Zeitler HP, Stürmer T, Brenner H. Prevalence of antibiotic resistance of Escherichia coli in the general population. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2002; 45: 130-137 [German].
7. Stürmer T, Erb A, Marre R, Brenner H. Prevalence and determinants of colonization with antibiotic resistant Escherichia coli in unselected patients attending general practitioners in Germany. Pharmacoepidemiol Drug Saf 2004; 13: 303-308.
8. German Institute for Standardization (DIN). Medical microbiology - Susceptibility testing of microbial pathogens to antimicrobial agents [Medizinische Mikrobiologie und Immunologie. E 58 940 Past 4 (Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (außer Mykobakterien) gegen Chemotherapeutika], Beuth-Verlag: Berlin.
9. Schwabe U, Paffrath D. Drug utilization report 2002. Springer-Verlag: Berlin, Heidelberg [German], 2003; pp. 142-143.
10. Reinert RR, Conrads G, Schlaeger JJ, Werner G, Witte W, Lutticken R, Klare I. Survey of antibiotic resistance among enterococci in North Rhine-Westphalia, Germany. J Clin Microbiol 1999; 37: 1638-1641.